The latest update is out from Consun Pharmaceutical Group Ltd. ( (HK:1681) ).
Consun Pharmaceutical Group Ltd. has received approval from the National Medical Products Administration to commence clinical trials for its SK-09 Tablet, a Category 1 chemical drug aimed at treating podocyte injury-related renal diseases such as diabetic nephropathy, focal segmental glomerulosclerosis, and minimal change diseases. This development is significant as there are currently no targeted therapies available for podocyte protection, and the SK-09 Tablet could provide a more precise and effective treatment option, potentially alleviating the burden on patients and the healthcare system.
More about Consun Pharmaceutical Group Ltd.
Consun Pharmaceutical Group Ltd., incorporated in the Cayman Islands, operates within the pharmaceutical industry, focusing on the development and commercialization of pharmaceutical products. The company is particularly involved in creating treatments for renal diseases through its wholly-owned subsidiary, Guangzhou Consun Pharmaceutical Company Limited.
YTD Price Performance: -9.22%
Average Trading Volume: 1,921
Technical Sentiment Signal: Strong Sell
Current Market Cap: €914.8M
Learn more about 1681 stock on TipRanks’ Stock Analysis page.